LOGIN  |  REGISTER

Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference

May 15, 2023 | Last Trade: US$101.58 0.62 0.61

MARLBOROUGH, Mass., May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.

Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute question-and-answer session with the host analyst at approximately 8:00 a.m. EDT. A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com.

The replay of the webcast will be accessible at investors.bostonscientific.com beginning approximately one hour following the completion of each event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

CONTACTS         

 

Media:                   

Investors:

Kate Haranis           

Lauren Tengler

508-683-6585 (office)   

508-683-4479 (office)

Media Relations               

Investor Relations

Boston Scientific Corporation   

Boston Scientific Corporation

This email address is being protected from spambots. You need JavaScript enabled to view it.             

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page